Enhancement of Immunity by a DNA Melanoma Vaccine against TRP2 with CCL21 as an Adjuvant
Open Access
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (1) , 194-202
- https://doi.org/10.1016/j.ymthe.2005.05.018
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Expansion of Melanoma-specific Cytolytic CD8+ T Cell Precursors in Patients with Metastatic Melanoma Vaccinated with CD34+ Progenitor-derived Dendritic CellsThe Journal of Experimental Medicine, 2004
- Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccineClinical Immunology, 2004
- Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor ImmunityClinical Cancer Research, 2004
- Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1Journal of Virology, 2003
- Immunomodulation of cancer: potential use of selectively replicating agentsJournal of Clinical Investigation, 2000
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000
- The Role of Chemokine Receptors in Primary, Effector, and Memory Immune ResponsesAnnual Review of Immunology, 2000
- Immunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated AntigensMolecular Therapy, 2000
- Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccineGene Therapy, 1999
- Phase I Study to the Immunotherapy of Metastatic Malignant Melanoma by a Cancer Vaccine Consisting of Autologous Cancer Cells Transfected with the Human IL-2 Gene. University of Vienna, AustriaHuman Gene Therapy, 1996